These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 28286977)

  • 121. A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy.
    Nishioka M; Okano N; Wakabayashi M; Ikeno T; Hayashi M; Mizutani T; Nagashima F; Furuse J
    Anticancer Res; 2024 Mar; 44(3):1233-1239. PubMed ID: 38423651
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer.
    Fan M; Deng G; Ma Y; Si H; Wang Z; Dai G
    BMC Cancer; 2024 Jan; 24(1):67. PubMed ID: 38216928
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Managing the economic impact of advanced pancreatic cancer.
    Soefje SA
    Am J Manag Care; 2019 Jan; 25(1 Suppl):S11-S16. PubMed ID: 30681820
    [TBL] [Abstract][Full Text] [Related]  

  • 124. The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
    Yang L; Su J; Wang W; Zhou F
    World J Surg Oncol; 2023 Jan; 21(1):19. PubMed ID: 36691032
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer.
    Kayahan N; Karaca M; Satış H; Yapar D; Özet A
    Turk J Med Sci; 2021 Aug; 51(4):1727-1732. PubMed ID: 33315355
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
    Gharaibeh M; McBride A; Bootman JL; Abraham I
    Br J Cancer; 2015 Apr; 112(8):1301-5. PubMed ID: 25791875
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.
    Bupathi M; Ahn DH; Wu C; Ciombor KK; Stephens JA; Reardon J; Goldstein DA; Bekaii-Saab T
    Med Oncol; 2016 Apr; 33(4):37. PubMed ID: 26995224
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Results of a single-arm pilot study of
    Ross PJ; Wasan HS; Croagh D; Nikfarjam M; Nguyen N; Aghmesheh M; Nagrial AM; Bartholomeusz D; Hendlisz A; Ajithkumar T; Iwuji C; Wilson NE; Turner DM; James DC; Young E; Harris MT
    ESMO Open; 2022 Feb; 7(1):100356. PubMed ID: 34953400
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.
    Charton E; Bachet JB; Hammel P; Desramé J; Chibaudel B; Cohen R; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Guerin-Meyer V; Taieb J; Volet J; Louvet C; Anota A; Bonnetain F
    Cancer Med; 2019 Sep; 8(11):5079-5088. PubMed ID: 31314957
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
    Vivaldi C; Crucitta S; Catanese S; Cucchiara F; Arrigoni E; Pecora I; Rofi E; Fornaro L; Salani F; Massa V; Vasile E; Morganti R; Danesi R; Del Re M
    Pharmacogenomics J; 2021 Apr; 21(2):233-242. PubMed ID: 33462346
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
    Carrato A; García P; López R; Macarulla T; Rivera F; Sastre J; Gostkorzewicz J; Benedit P; Pérez-Alcántara F
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):579-89. PubMed ID: 25991037
    [TBL] [Abstract][Full Text] [Related]  

  • 132. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study.
    Lazzaro C; Barone C; Caprioni F; Cascinu S; Falcone A; Maiello E; Milella M; Pinto C; Reni M; Tortora G
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):435-446. PubMed ID: 29641931
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
    Ide Y; Otsuka T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Shinohara Y; Ueno S; Taguchi H; Honda T; Shibuki T; Nio K; Ureshino N; Mizuta T; Mitsugi K; Shirakawa T
    Anticancer Res; 2023 Apr; 43(4):1817-1826. PubMed ID: 36974805
    [TBL] [Abstract][Full Text] [Related]  

  • 134. A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers.
    Wang Y; Camateros P; Cheung WY
    J Gastrointest Cancer; 2019 Mar; 50(1):62-68. PubMed ID: 29143916
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery.
    Jung JH; Won SH; Jung K; Lee JS; Lee JC; Kim JW; Yoon YS; Hwang JH; Han HS; Kim J
    Gut Liver; 2024 Jul; 18(4):737-746. PubMed ID: 38146258
    [TBL] [Abstract][Full Text] [Related]  

  • 136. A population-based analysis of urban-rural disparities in advanced pancreatic cancer management and outcomes.
    Canale TD; Cho H; Cheung WY
    Med Oncol; 2018 Jul; 35(8):116. PubMed ID: 29974267
    [TBL] [Abstract][Full Text] [Related]  

  • 137. [Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use].
    Ferris Villanueva E; Martínez Penella M; Cerezuela Fuentes P; Guerrero Bautista R; García Márquez A; Mira Sirvent Mdel C
    Farm Hosp; 2015 May; 39(3):181-5. PubMed ID: 26005895
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
    Chiorean EG; Von Hoff DD; Tabernero J; El-Maraghi R; Ma WW; Reni M; Harris M; Whorf R; Liu H; Li JS; Manax V; Romano A; Lu B; Goldstein D
    Br J Cancer; 2016 Jul; 115(2):188-94. PubMed ID: 27351217
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Complete response to chemotherapy in a 6-year survivor of metastatic pancreatic cancer.
    Burke CE; Eng NL; Yee NS; Peng JS
    BMJ Case Rep; 2024 Jul; 17(7):. PubMed ID: 39038872
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
    Mie T; Sasaki T; Okamoto T; Takeda T; Mori C; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
    Jpn J Clin Oncol; 2022 Dec; 52(12):1399-1407. PubMed ID: 36111430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.